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Clinicians, patients, governments, third-party payers, and the public take for granted that diagnostic tests are
accurate, safe and effective. However, we may be seriously misled if we are relying on robust study design to
ensure accurate, safe, and effective diagnostic tests. Properly conducted, randomized controlled trials are the gold
standard for assessing the effectiveness and safety of interventions, yet are rarely conducted in the assessment of
diagnostic tests. Instead, diagnostic cohort studies are commonly performed to assess the characteristics of a
diagnostic test including sensitivity and specificity. While diagnostic cohort studies can inform us about the relative
accuracy of an experimental diagnostic intervention compared to a reference standard, they do not inform us
about whether the differences in accuracy are clinically important, or the degree of clinical importance (in other
words, the impact on patient outcomes). In this commentary we provide the advantages of the diagnostic
randomized controlled trial and suggest a greater awareness and uptake in their conduct. Doing so will better
ensure that patients are offered diagnostic procedures that will make a clinical difference.
Keywords: Clinical trials, diagnostic tests, randomizationBackground
Clinicians rely heavily on diagnostic procedures to de-
cide whether patients have or do not have a given condi-
tion or disease. Clinicians, patients, governments, third-
party payers, and the public take for granted that such
diagnostic tests are accurate, safe and effective. Yet what
is the evidence that they are accurate, safe, and effective?
If robust study design is the yardstick, we may be ser-
iously misled. Properly conducted, randomized con-
trolled trials are the gold standard for assessing the
effectiveness and safety of interventions. While the pub-
lication of randomized trials of non-therapeutic inter-
ventions such as surgical procedures and behavioral
interventions lag far behind those of drugs in number,
randomized trials of diagnostic procedures are an even
rarer species. To our knowledge, reasons for their lack
of conduct have not been explored but may include the
resources, sample size, and interdisciplinary teamwork* Correspondence: dafergusson@ohri.ca
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reproduction in any medium, provided the orrequired. Moreover, regulatory approval does not require
randomized trials in their decision making. In order to
adequately assess the diagnostic characteristics, as well
as the impact on clinical outcomes without bias, we sug-
gest that the evaluation of diagnostic interventions move
beyond traditional diagnostic study designs to diagnostic
randomized controlled trials.
To illustrate the need for diagnostic randomized con-
trolled trials, consider the following scenario:
A patient presents to the emergency department with
a painful swollen leg and the emergency room resident
suspects deep vein thrombosis (DVT) (Figure 1). The
emergency room resident outlines a diagnostic manage-
ment plan for the emergency room physician. He
suggests a D-Dimer and a leg ultrasound be done simul-
taneously. The emergency room physicians points out
that “if you are ordering an ultrasound why bother with
ordering a D-Dimer if the patient has a low pre-test
probability without diagnostic imaging?” The emergency
resident pulls out a published diagnostic randomized
controlled trial comparing a strategy of using D-Dimer
after ultrasound (and venography if the D-Dimer is posi-
tive and ultrasound is negative) compared to serial ultra-
sounds alone without D-Dimer [1]. This diagnosticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Deep vein thrombosis occurs when a blood clot develops in a leg vein. If the blood clot is  
in the large veins of the thigh it can be life threatening. If the blood clot develops in the   
small veins of the calf it can only become life threatening if it grows and involves the 
large veins of the thigh. If it will grow it will typically do so in the next week or so.  
Venography, direct contrast injection and visualisation of all leg veins, calf and thigh, is 
the gold standard but is painful, expensive and exposes patients to contrast dye (allergies  
and possible renal dysfunction). Ultrasound of the legs is non-invasive and inexpensive  
but has limited sensitivity and specificity for calf DVT. To get around the limited 
sensitivity of ultrasound for calf DVT serial ultrasounds can be done a week later. These  
serial ultrasounds are done to ensure that a calf blood clot hasn’t grown into a dangerous  
thigh blood clot. D-Dimers are a blood test that detect any evidence of blood clotting  
(even getting a bruise may cause a positive D-Dimer). D-Dimers are sensitive but non-
specific for DVT and as such are helpful for ruling out DVT in patients with low pre-test 
probability.
Figure 1 Primer on venous thrombosis.
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and ultrasound approach picked up 4% more DVTs than
the serial ultrasound approach “so it is a superior ap-
proach as it is much more sensitive and specific”. The
emergency room physician who also read the same
paper points out that after follow-up there were no dif-
ferences in important clinical outcomes between the two
diagnostic strategies. Furthermore, the likely discrepancy
is that the D-Dimer and ultrasound approach “picks up”
more clinically insignificant calf blood clots. This ex-
ample highlights important differences in diagnostic
accuracy between cohort studies and diagnostic rando-
mized controlled trials. The resident was interpreting
the study by solely focusing on the diagnostic character-
istics while ignoring clinically relevant outcomes.
Main text
The cohort design
The prevailing study design for investigating a new diag-
nostic test is a prospective blind comparison of the ex-
perimental test and the diagnostic reference standard
(“gold standard”) in a consecutive series of patients from
a representative clinical population [2-4]. In these pro-
spective diagnostic accuracy cohort studies, patients with
suspected disease undergo both an experimentaldiagnostic intervention and the diagnostic reference stand-
ard (Figure 2). Diagnostic accuracy or the performance of
the experimental diagnostic intervention is measured
using a 2×2 table, and sensitivity, specificity, likelihood
ratios, diagnostic odd ratios and accuracy can be calcu-
lated. Indeed, much literature has been published on the
standards that should be met when evaluating diagnostic
studies and this literature is primarily focused on diagnos-
tic accuracy cohort studies [2-5]. The advantages of a
diagnostic accuracy cohort study include their simplicity
to perform, they are relatively inexpensive, and they are
well accepted among the medical research community.
They are appropriate for the early investigation of an ex-
perimental diagnostic test to determine if it is appropriate
to continue investigating the experimental diagnostic test.
However, while providing diagnostic accuracy information,
diagnostic accuracy cohort studies are not directly tied to
patient outcomes (Figure 2). Indeed, we often forget that
diagnostic tests alone do not improve patient outcomes.
Only when diagnostic accuracy is coupled with effective
therapy (or noxious therapy) can outcomes be influenced.
The diagnostic randomized controlled trial
Twenty-five years ago, Guyatt and colleagues proposed
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Figure 3 Open diagnostic intervention randomized controlled trial.
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effects, at least as accurate as existing technologies,
eliminate the need for other diagnostic interventions,
without loss of accuracy or lead to the institution of ef-
fective therapy” [6]. They further stated that “establish-
ing patient benefit often requires randomized controlled
trials”. This call to action continues to be advocated in
the literature but largely ignored [7,8].
We define diagnostic randomized controlled trials as
randomized comparisons of two diagnostic interventions
(one standard and one experimental) with identical
therapeutic interventions based on the results of the
competing diagnostic interventions (for example, disease:
yes or no) and with the study outcomes being clinically
important consequences of diagnostic accuracy (Figures 3
and 4). While diagnostic cohort studies inform us about
the relative accuracy of an experimental diagnostic inter-
vention compared to a reference standard, they do not
inform us about whether the differences in accuracy are
clinically important, or the degree of clinical importance
(in other words, the impact on patient outcomes).
We propose that conducting diagnostic randomized
controlled trials is critical in the evaluation of diagnostic
technologies and, in particular, novel technologies in the
presence of standard diagnostic tests. Our reasons in-
clude the following: 1) diagnostic randomized controlled
trials permit a direct comparison of the experimental
test to the standard test with clinically relevant out-
comes as opposed to simply comparing them to each
other; 2) diagnostic randomized controlled trials can re-
sult in the experimental test being better than the refer-
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Figure 4 Blind diagnostic intervention randomized controlled trial.
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trolled trials can be conducted where there is no
accepted reference standard (which cannot be done with
diagnostic cohort studies); 4) test properties (sensitivity,
specificity, likelihood ratios, accuracy etc.) can still be
calculated in diagnostic randomized controlled trials if
the reference standard is conducted and the results kept
blinded in the experimental group and the results of the
experimental tests are conducted but kept blinded in the
reference group; and 5) diagnostic technologies could be
compared across disciplines to help policy makers decide
in which new diagnostic technologies to invest.
The value of the diagnostic randomized controlled trial
design
In our example, the therapeutic response to the diagnos-
tic question is whether to anticoagulate patients with
confirmed DVT to prevent recurrent DVT. In the study
by Kearon and colleagues [1] outcome event rates were
not different, likely by virtue of missing clinically unim-
portant DVT in the serial ultrasound approach.Venography is considered the reference standard for
DVT. Diagnostic accuracy cohort studies would conclude
that nothing could beat the “gold standard”. However, one
could imagine a new test that does not diagnose clinically
insignificant DVT (in other words, more specific for clinic-
ally relevant DVT) but identifies small DVT that venog-
raphy might miss that will grow and ultimately become
clinically significant. For Star Trek fans we will call this the
“important clot tri-corder”. If the tri-corder were compared
to venography in a diagnostic accuracy cohort study only,
we might abandon the technology because of insensitivity
for small inconsequential DVT. However, if a diagnostic
randomized controlled trial were conducted, it is possible
that we demonstrate its superiority to venography.
If venography were abolished by decree from govern-
ment, we would not be left unable to evaluate diagnostic
technologies for DVT. If we adopted diagnostic rando-
mized controlled trials, the “important clot tri-corder”
could be compared to serial ultrasounds and with clin-
ical relevant important outcomes and then we could de-
cide if the tri-corder should be adopted.





Context bias Experimental test more likely to be
reported as abnormal in populations
with high disease prevalence
Clinical review bias Experimental test or reference standard
interpreted with knowledge of
participant clinical characteristics
Test review bias Experimental test interpreted with
knowledge of the reference standard
test results
Diagnostic review bias Reference standard test interpreted with
knowledge of the experimental test results
External validity (generalizability)




Limited challenge bias Potential study participants with
confounders known to influence
experimental test accuracy excluded
from study
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frequently either indeterminate (inadequate contrast fill-
ing of veins) or cannot be done (unable to obtain
venipuncture, contrast dye allergies, renal dysfunction).
The 2 × 2 table and measures of diagnostic accuracy do
not reflect this limitation of the test in actual practice
nor the spectrum bias introduced by omitting these
patients. The rate of indeterminate or “cannot be done
tests” may be provided in manuscripts permitting the
reader to contemplate the generalizability of a diagnostic
cohort study to their setting but the rate of indetermin-
ate or cannot be done tests is often omitted from publi-
cations of diagnostic cohort studies [9,10]. Diagnostic
randomized controlled trials analyzed by “intention-
to-test” would incorporate these often neglected out-
come effects of either indeterminate tests or tests that
could not be done in both arms of a trial. Furthermore,
beyond generalizability, it is plausible that patients with
indeterminate tests or tests that could not be done are
different than those with determinate tests, and that
these differences may confound the accuracy of a diag-
nostic test (in other words, spectrum bias). For example,
venograms often cannot be done in patients with a lot of
edema due to the inability to obtain a venipuncture for
the procedure. However edema is a sign of important
venous thrombosis (caused by large vein obstruction; for
example, thigh veins). In a diagnostic cohort study, these
patients would be excluded from the accuracy analysis
and this will lead to a bias against the experimental diag-
nostic test. The important “clot tri-corder” would have
made the diagnosis but given that fewer patients with
thigh vein thrombosis relative to calf vein thrombosis
(where there is usually less edema) would be included in
the diagnostic accuracy analysis versus venogram, the
tri-corder would seemingly have lower sensitivity. A
diagnostic randomized controlled trial intention-to-test
analysis would eliminate this bias.
Diagnostic accuracy can still be determined in a diag-
nostic randomized controlled trial when the gold stand-
ard and the experimental diagnostic test are conducted
but the results of one test are randomly kept blinded
(Figure 4). In our example, both the tri-corder and ven-
ography could be conducted by the radiologist and only
the result of the randomly assigned test are disclosed to
the treating physician. Patient outcomes are then evalu-
ated on follow-up. Diagnostic accuracy (sensitivity, spe-
cificity, likelihood ratios, accuracy etc.) of the tri-corder
could still be reported at the conclusion of the trial in
comparison to venography.
Discussion
If the minister of health were trying to decide whether
to invest in the tri-corder for DVT diagnosis or positron
emission tomography (PET) scanning for early detectionof lung cancer in patients with a lung mass, they could
not make an informed decision based on diagnostic ac-
curacy studies as these are only indirectly related to clin-
ically relevant outcomes (mortality, surrogates of
mortality, quality of life). However, if they had access to
two diagnostic randomized controlled trials with clinic-
ally relevant outcomes, they could make a more
informed decision on which technology to invest in (for
example, one study comparing the tri-corder to venog-
raphy with mortality as the outcome and a second study
comparing computed tomography chest scanning to
PET scanning for investigation of a lung mass with mor-
tality as the outcome).
Diagnostic randomized controlled trials also eliminate
or reduce the likelihood for many of the potential biases
that threaten internal validity of diagnostic accuracy co-
hort studies (Table 1). Randomization ensures that dif-
ferential context bias is eliminated as both competing
strategies would be evaluated in groups with similar dis-
ease prevalence. Clinicians often make between-study
comparisons in interpreting the literature on diagnostic
accuracy, increasing the likelihood of misinterpretation
due to influence of disease prevalence on diagnostic ac-
curacy measures (for example, predictive values). For ex-
ample, ultrasound for DVT has much higher negative
predictive values in low-risk community studies com-
pared to high-risk inpatient studies. Conducting diag-
nostic randomized controlled trials of competing
diagnostic strategies also reduces the risk of false conclu-
sions from selection bias (patient populations with vary-
ing risks of false diagnosis); if adequate numbers of
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the groups are balanced. For example, after a DVT there
is often incomplete resolution leading to residual ultra-
sound abnormalities (that are not fresh dangerous clots
but hard, often walled off, scars that are not at risk of
embolizing). Randomization would ensure that these
patients are balanced between the “tri-corder” group and
venogram group and not drive the findings of our stud-
ies. On the other hand, a diagnostic accuracy study com-
paring the “tri-corder” to the venogram with a high
prevalence of patients with prior DVT may conclude
that the tri-corder missed a lot of DVTs (which were in
fact old); in other words, conclude low sensitivity and
low negative predictive values. Furthermore, examining
an identical study with no patients with prior DVT
would lead to higher sensitivity and negative predictive
values. Differential clinical review is less likely to occur
in a diagnostic randomized controlled trial as patient
characteristics should be balanced in the different arms
of a diagnostic randomized controlled trial. Test review
and reference review bias are unlikely to occur with a
diagnostic randomized controlled trial as the results are
acted upon independently of the results of the alterna-
tive test. In diagnostic accuracy cohort studies, where
both tests are conducted on a single patient, the tests
are not necessarily independent of each other. An ex-
ample is that venography has been thought to perhaps
cause DVT. If the tri-corder were performed the next
day after a negative venography and detected a DVT we
would conclude that the tri-corder has identified a false
positive. This would not occur in the diagnostic cohort
study and, furthermore, would allow us to identify harm
caused by diagnostic tests by having a reference group to
compare incidences of adverse events.
Bossuyt and colleagues [11] have stated that rando-
mized trials of diagnostic procedures offer several advan-
tages over other design options, but they raise the
important issue of efficiency. Specifically, randomizing
patients who test positive to both diagnostic procedures
or negative to both procedures may be inefficient as they
do not contribute to the between-diagnostic comparison
and their outcomes would be determined solely by the
treatment not the test. Thus, only randomizing discord-
ant patients (in other words, positive to one and negative
to the other) to treatment arms would lead to better
study efficiency. They offer an alternative design in
which a cohort of patients would receive both diagnostic
procedures and those patients with discordant findings
would be randomized to different treatment strategies.
However, the status of discordance would be known to
treating staff at the time of randomization which could
influence participation in the trial or treatment choices
when randomized based on ambiguity of diagnosis. In
addition, trying to consent patients and treating staffwith known discordant status will likely further hamper
recruitment. Second, discordant patients may have dif-
ferent demographic and clinical characteristics than con-
cordant patients which could influence subsequent
outcome rates and thus results may not be as
generalizable as a diagnostic randomized trial.
As with any randomized trial, investigators need to en-
sure there is clinical equipoise between the interven-
tions. For diagnostic randomized controlled trials,
patients cannot be placed in a position of being rando-
mized to a known inferior diagnostic procedure for the
sake of research. Investigators must substantiate clearly
that the interventions are in diagnostic equipoise.
While randomized trials are the gold standard for
establishing effectiveness, they are generally more expen-
sive and resource intensive than traditional research
methods. Given the routine use of diagnostic procedures
and their costs, we maintain that sacrificing validity of
results with suboptimal designs is not prudent. Rando-
mized controlled trials remain the standard study design
for the approval of drugs and we feel the evaluation of
diagnostic procedures should be treated no differently.
Conclusion
Given the inherent limitations of diagnostic cohort stud-
ies, we suggest a greater awareness and uptake in the
conduct of diagnostic randomized controlled trials.
Doing so will better ensure that patients are offered ef-
fective diagnostic procedures that will make a clinical
difference. The evaluation of diagnostic tests should be
treated no differently than other interventions. The pau-
city of published diagnostic randomized controlled trials
suggests we have a long way to go.
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